Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genomic Predictors of Response to Metastasis-directed Therapy With or Without Androgen Deprivation Therapy.

European urology oncology - 1 Apr 2026

Sutera Philip, Van der Eecken Kim, Song Yang, Shetty Amol C, Davicioni Elai, Proudfoot James A, Hakansson Alexander, English Keara, Wang Jarey, Guler Ozan Cem, Bazyar Soha, Verbeke Sofie, Van Dorpe Jo, Fonteyne Valérie, De Laere Bram, Hathout Lara, Ennis Ronald, Jabbour Salma K, Saraiya Biren, Stephenson Ryan, Mayer Tina, Mishra Mark, Rana Zaker, Molitoris Jason, Kiess Ana, Song Daniel Y, DeWeese Theodore, Pienta Kenneth J, Tran Phuoc T, Berlin Alejandro, Onal Cem, Ost Piet, Deek Matthew P

Abstract excerpt

Metastasis-directed therapy (MDT) is an emerging treatment option for metachronous oligometastatic castration-sensitive prostate cancer (omCSPC) and can delay time to progression and the need to initiate androgen deprivation therapy (ADT). However, optimal ways to synergize MDT and ADT are not known, and better personalization of MDT is needed. We examined the role of combined ADT and MDT and the ability of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Androgen Antagonists

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Ataxia Telangiectasia Mutated Proteins

Share to BRCA1 Protein

Share to BRCA2 Protein

Share to Neoplasm Metastasis

Share to Prostatic Neoplasms, Castration-Resistant

Share to Retinoblastoma Binding Proteins

Share to Ubiquitin-Protein Ligases

Source

Open in PubMed Open full text

Identifiers

PMID: 40976747
DOI: 10.1016/j.euo.2025.07.007
PMCID: PMC13401512

Genes

ATM
BRCA1
TP53

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genomic Predictors of Response to Metastasis-directed Therapy With or Without Androgen Deprivation Therapy.PMID 40976747Read ↗

Integration of genomic classification and clinical characteristics predicts survival in metastatic prostate cancerSemantic proximity Read ↗

Prognostic value of genomic mutations in metastatic prostate cancerSemantic proximity Read ↗

Blood-Based Genomic Alteration Signature for Predicting Progression-Free Survival in De Novo Metastatic Hormone-Sensitive Prostate Cancer: A Real-World Study.Semantic proximity Read ↗

Metastatic Prostate Cancers with BRCA2 versus ATM Mutations Exhibit Divergent Molecular Features and Clinical Outcomes.Semantic proximity Read ↗

Additive Clinical Utility of Microsatellite Instability and Tumor Mutational Burden to Predict Immune Checkpoint Inhibitor Effectiveness in Metastatic Castration-Resistant Prostate Cancer.Semantic proximity Read ↗

An Emerging Landscape for Canonical and Actionable Molecular Alterations in Primary and Metastatic Prostate Cancer.Semantic proximity Read ↗

Treatment patterns and outcomes in metastatic castration-resistant prostate cancer patients with and without somatic or germline alterations in homologous recombination repair genes.Semantic proximity Read ↗

First-line combination treatment with PARP and androgen receptor–signaling inhibitors in HRR-deficient mCRPC: Applying clinical study findings to clinical practice in the United StatesSemantic proximity Read ↗

Impact of homologous recombination repair gene mutations on survival in metastatic prostate cancer: A real-world analysis from an observational database.Semantic proximity Read ↗

Genomic predictors of prostate cancer therapy outcomes.Semantic proximity Read ↗

The prevalence of gene mutations in homologous recombination repair pathways in Japanese patients with metastatic castration-resistant prostate cancer in real-world clinical practice: The multi-institutional observational ZENSHIN study.Semantic proximity Read ↗

Prognostic Expression Signature of RB1, PTEN, and TP53 Genes in Patients with Metastatic Hormone-sensitive Prostate Cancer Treated with Androgen Receptor Pathway InhibitorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.